GlassScriptPhysician profile
Regina K Lee
NPI 1487787461
$18,889.51
in general payments reported to CMS, 2019-2025
74 companies · $1,706 in 2025
The $1,706 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,869 · 2020: $2,247 · 2021: $3,510 · 2022: $3,181 · 2023: $2,661 · 2024: $2,716 · 2025: $1,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,083.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,046.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,656.95 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,395.10 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Abbvie INC. | $1,280.72 | 2021-2025 | |
| Lilly USA, LLC | $1,213.66 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Avanir Pharmaceuticals, INC. | $774.23 | 2019-2022 | |
| Pfizer INC. | $605.38 | 2020-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $485.64 | 2022 | |
| Ironshore Pharmaceuticals INC. | $463.53 | 2019-2023 | Jornay Pm |
| Merck Sharp & Dohme LLC | $403.44 | 2019-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Biohaven Pharmaceuticals, INC. | $387.49 | 2021 | |
| Abbott Laboratories | $368.05 | 2021-2025 | Xience Skypoint, Freestyle Libre 3, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.09 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $362.65 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $349.19 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.